Literature DB >> 24299477

Development of clinical guidelines for the prescription of a seated wheelchair or mobility scooter for people with traumatic brain injury or spinal cord injury.

Sue Lukersmith1, Lesley Radbron, Katherine Hopman.   

Abstract

BACKGROUND/AIM: Providing a wheelchair or scooter is a complex therapy intervention aimed at enhancing the person's functioning. The research and experience has shown that a wheelchair which is poorly matched to the individual, adversely affects potential activities and participation, lifestyle goals, health status and can be costly. The development of an evidence-based clinical guideline will provide a synthesis of the evidence and recommendations for best practice.
METHODS: The guidelines were developed using a rigorous methodology of systematic search for primary studies, critical appraisal and synthesis of the evidence using an adaptation of the National Health and Medical Research Council recommendation grades in conjunction with a multidisciplinary working party.
RESULTS: Seventy-six recommendations were developed from 44 clinical questions related to goals, assessment and review, capacity and performance, upper limb capacity and injury risk, wheelchair features, propulsion, training, transport and maintenance. Resources were developed to support the use of the guidelines. Only examples of recommendations are provided here. The complete guidelines and technical report should be downloaded from http://www.lifetimecare.nsw.gov.au/Brain_Injury.aspx.
CONCLUSION: The guidelines provide appraisal and synthesis of the literature and recommendations for best practice on the prescription of a wheelchair or scooter for adults with spinal cord injury and/or traumatic brain injury. The guidelines are intended to reduce the potential for poor wheelchair prescription, inform and guide practice to enhance outcomes. Through judicious application of the available research, these guidelines provide best practice recommendations for prescribing the most appropriate wheelchair for a person with a traumatic brain injury/spinal cord injury.
© 2013 Occupational Therapy Australia.

Entities:  

Keywords:  functioning; guidelines; occupational therapist; scooter; wheelchair

Mesh:

Year:  2013        PMID: 24299477     DOI: 10.1111/1440-1630.12077

Source DB:  PubMed          Journal:  Aust Occup Ther J        ISSN: 0045-0766            Impact factor:   1.856


  6 in total

1.  Mobility scooters in urban environments: A research agenda.

Authors:  Michal Isaacson; Dov Barkay
Journal:  J Transp Health       Date:  2020-08-13

2.  Evidence-Based Strategies for Preserving Mobility for Elderly and Aging Manual Wheelchair Users.

Authors:  Philip S Requejo; Jan Furumasu; Sara J Mulroy
Journal:  Top Geriatr Rehabil       Date:  2015 Jan-Mar

3.  SenseJoy, a pluggable solution for assessing user behavior during powered wheelchair driving tasks.

Authors:  Olivier Rabreau; Sylvain Chevallier; Luc Chassagne; Eric Monacelli
Journal:  J Neuroeng Rehabil       Date:  2019-11-06       Impact factor: 4.262

4.  Asynchronous and Tailored Digital Rehabilitation of Chronic Shoulder Pain: A Prospective Longitudinal Cohort Study.

Authors:  Dora Janela; Fabíola Costa; Maria Molinos; Robert G Moulder; Jorge Lains; Gerard E Francisco; Virgílio Bento; Steven P Cohen; Fernando Dias Correia
Journal:  J Pain Res       Date:  2022-01-08       Impact factor: 3.133

5.  Development of the Canadian Spinal Cord Injury Best Practice (Can-SCIP) Guideline: Methods and overview.

Authors:  Eleni M Patsakos; Mark T Bayley; Ailene Kua; Christiana Cheng; Janice Eng; Chester Ho; Vanessa K Noonan; Matthew Querée; B Catharine Craven
Journal:  J Spinal Cord Med       Date:  2021       Impact factor: 1.985

6.  Evaluation of the quality of published SCI clinical practice guidelines using the AGREE II instrument: Results from Can-SCIP expert panel.

Authors:  Eleni M Patsakos; B Catharine Craven; Ailene Kua; Christiana L Cheng; Janice Eng; Chester Ho; Vanessa K Noonan; Matthew Querée; Mark T Bayley
Journal:  J Spinal Cord Med       Date:  2021       Impact factor: 1.985

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.